A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma
A Phase 1b, Multicenter, Open-Label, Study to Investigate the Safety and Efficacy of CLN-619 (anti-MICA/MICB Antibody) in Patients with Relapsed and Refractory Multiple Myeloma
Multiple Myeloma
DRUG: CLN-619
Proportion of participants reporting Adverse Events (AEs) and Serious Adverse Events (SAEs), Incidence of AEs and SAEs using MedDRA, baseline through 3-week treatment period|Changes in Eastern Cooperative Oncology Group (ECOG) performance, ECOG Scores are a functional scale ranging from 0 (Fully active, able to carry out all pre-disease activities without restrictions) to 5 (Death), Up to 2 years|Incidence of Dose-Limiting toxicity (DLTs), Maximum Tolerated Dose (MTD) is reached if 2 or more patients experience a DLT at a dose level, up to 2 years|Best Overall Response (BOR) per patient, The best response defined by the International Myeloma Working Group (IMWG) criteria recorded throughout the study including unscheduled assessments, up to 2 years|Overall Response Rate (ORR), The proportion of patients who achieve a partial response or better (e.g., Partial Response (PR), Very Good Partial Response (VGPR), Complete Response (CR) or stringent Complete Response (sCR), according to IMWG response criteria, up to 2 years|Duration of Response (DoR), The time from the earliest date of documented response to the first documented disease progression or death, whichever occurs first., up to 2 years|Clinical Benefit Rate (CBR), The proportion of patients with a best overall response of CR, PR and stable disease (SD), according to IMWG response criteria, up to 2 years|Progression Free Survival (PFS), The time from date of first dose until the earliest date of disease progression, or death from any cause, whichever occurs first., up to 2 years|Overall Survival (OS), Time from the date of first dose to date of death due to any cause., up to 2 years
A Phase 1b, Multicenter, Open-Label, Study to Investigate the Safety and Efficacy of CLN-619 (anti-MICA/MICB Antibody) in Patients with Relapsed and Refractory Multiple Myeloma